189 related articles for article (PubMed ID: 17895401)
1. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Barlogie B; Tricot G; Haessler J; van Rhee F; Cottler-Fox M; Anaissie E; Waldron J; Pineda-Roman M; Thertulien R; Zangari M; Hollmig K; Mohiuddin A; Alsayed Y; Hoering A; Crowley J; Sawyer J
Blood; 2008 Jan; 111(1):94-100. PubMed ID: 17895401
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.
Papanikolaou X; Rosenbaum ER; Tyler LN; Sawyer J; Heuck CJ; Barlogie B; Cottler-Fox M
Leukemia; 2014 Apr; 28(4):888-93. PubMed ID: 23852547
[TBL] [Abstract][Full Text] [Related]
3. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies.
Micallef IN; Lillington DM; Apostolidis J; Amess JA; Neat M; Matthews J; Clark T; Foran JM; Salam A; Lister TA; Rohatiner AZ
J Clin Oncol; 2000 Mar; 18(5):947-55. PubMed ID: 10694543
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
Horvath N; Hahn U; Joshua D; Dyson P; Gibson J; Stevens J; Rawling T; Barrow L; Brown R; Stephens S; Gower G; Norman J; Mills B; To LB
Intern Med J; 2004 Apr; 34(4):167-75. PubMed ID: 15086696
[TBL] [Abstract][Full Text] [Related]
5. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
[TBL] [Abstract][Full Text] [Related]
6. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
7. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
Jacobson J; Barlogie B; Shaughnessy J; Drach J; Tricot G; Fassas A; Zangari M; Giroux D; Crowley J; Hough A; Sawyer J
Br J Haematol; 2003 Aug; 122(3):430-40. PubMed ID: 12877670
[TBL] [Abstract][Full Text] [Related]
8. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Krishnan A; Bhatia S; Slovak ML; Arber DA; Niland JC; Nademanee A; Fung H; Bhatia R; Kashyap A; Molina A; O'Donnell MR; Parker PA; Sniecinski I; Snyder DS; Spielberger R; Stein A; Forman SJ
Blood; 2000 Mar; 95(5):1588-93. PubMed ID: 10688812
[TBL] [Abstract][Full Text] [Related]
9. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
10. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
[TBL] [Abstract][Full Text] [Related]
11. Deletion 5q31 in patients with stable, melphalan-treated multiple myeloma.
Amiel A; Fridman K; Elis A; Gaber E; Manor Y; Fejgin M; Lishner M
Cancer Genet Cytogenet; 1999 Aug; 113(1):45-8. PubMed ID: 10459345
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
14. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
Chakraborty S; Sun CL; Francisco L; Sabado M; Li L; Chang KL; Forman S; Bhatia S; Bhatia R
J Clin Oncol; 2009 Feb; 27(5):791-8. PubMed ID: 19124806
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
Fermand JP; Ravaud P; Chevret S; Divine M; Leblond V; Belanger C; Macro M; Pertuiset E; Dreyfus F; Mariette X; Boccacio C; Brouet JC
Blood; 1998 Nov; 92(9):3131-6. PubMed ID: 9787148
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J
Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Maia C; Puig N; Cedena MT; Goicoechea I; Valdes-Mas R; Vazquez I; Chillon MC; Aguirre P; Sarvide S; Gracia-Aznárez FJ; Alkorta G; Calasanz MJ; Garcia-Sanz R; Gonzalez M; Gutierrez NC; Martinez-Lopez J; Perez JJ; Merino J; Moreno C; Burgos L; Alignani D; Botta C; Prosper F; Matarraz S; Orfao A; Oriol A; Teruel AI; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Rosiñol L; Mateos MV; Lahuerta JJ; Blade J; San Miguel JF; Paiva B
Blood; 2020 Jun; 135(26):2375-2387. PubMed ID: 32299093
[TBL] [Abstract][Full Text] [Related]
18. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
[TBL] [Abstract][Full Text] [Related]
19. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS
J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056
[TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]